Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation

Coya Therapeutics Inc COYA reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for mild to moderate Alzheimer's Disease.

Last month, Coya reported that COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015). 

Clinically, evaluation of cognitive function showed that administration of COYA 301 resulted in a statistically significant improvement in mean MMSE scores during the treatment phase, compared to mean MMSE score at baseline (p=0.015). 

Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the end of treatment with COYA 301, compared to pre-treatment baseline scores, indicating no cognitive decline.

COYA 301 administration resulted in a statistically significant reduction of blood biomarkers and peripheral expression of the proinflammatory cytokines.

The consistent reduction of these cytokines correlated with a lack of cognitive decline in the patients throughout the study. 

Further, the significant reduction of proinflammatory cytokine expression and the lack of clinical decline also correlated with a significant increase of regulatory T cell function following the administration of COYA 301.

Price Action: COYA shares are up 4.61% at $4.54 on the last check Wednesday.